Literature DB >> 18836859

Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma.

Andrzej Zieleniak1, Marzena Wójcik, Lucyna A Woźniak.   

Abstract

The peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone receptor superfamily. To date, three different PPAR isotypes, namely PPAR-alpha, -delta, and -gamma, have been identified in vertebrates and have distinct patterns of tissue distribution. Like all nuclear receptors, the human PPAR-gamma (hPPAR-gamma) is characterized by a modular structure composed of an N-terminal A/B domain, a DNA-binding domain with two zinc fingers (C domain), a D domain, and a C-terminal ligand-binding domain (E/F domain). Human PPAR-gamma exists in two protein isoforms, hPPAR-gamma(1) and -gamma(2), with different lengths of the N-terminal. The hPPAR-gamma(2) isoform is predominantly expressed in adipose tissue, whereas hPPAR-gamma(1) is relatively widely expressed. Human PPAR-gamma plays a critical physiological role as a central transcriptional regulator of both adipogenic and lipogenic programs. Its transcriptional activity is induced by the binding of endogenous and synthetic lipophilic ligands, which has led to the determination of many roles for PPAR-gamma in pathological states such as type 2 diabetes, atherosclerosis, inflammation, and cancer. Of the synthetic ligands, the thiazolidinedione class of insulin-sensitizing drugs (ciglitazone, pioglitazone, troglitazone, rosiglitazone) is employed clinically in patients with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18836859     DOI: 10.1007/s00005-008-0037-y

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  43 in total

Review 1.  Gadd45 proteins: relevance to aging, longevity and age-related pathologies.

Authors:  Alexey A Moskalev; Zeljka Smit-McBride; Mikhail V Shaposhnikov; Ekaterina N Plyusnina; Alex Zhavoronkov; Arie Budovsky; Robi Tacutu; Vadim E Fraifeld
Journal:  Ageing Res Rev       Date:  2011-10-05       Impact factor: 10.895

Review 2.  Pharmacological Modulation of Lung Carcinogenesis in Smokers: Preclinical and Clinical Evidence.

Authors:  Silvio De Flora; Gancho Ganchev; Marietta Iltcheva; Sebastiano La Maestra; Rosanna T Micale; Vernon E Steele; Roumen Balansky
Journal:  Trends Pharmacol Sci       Date:  2015-12-23       Impact factor: 14.819

3.  PPARgamma differentially regulates energy substrate handling in brown vs. white adipose: focus on "The PPARgamma agonist rosiglitazone enhances rat brown adipose tissue lipogenesis from glucose without altering glucose uptake".

Authors:  Justin L Grobe; Marcia Venegas-Pont; Curt D Sigmund; Michael J Ryan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-03-04       Impact factor: 3.619

4.  Molecular causes of transcriptional response: a Bayesian prior knowledge approach.

Authors:  Kourosh Zarringhalam; Ahmed Enayetallah; Alex Gutteridge; Ben Sidders; Daniel Ziemek
Journal:  Bioinformatics       Date:  2013-09-26       Impact factor: 6.937

Review 5.  The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases.

Authors:  Je-Min Choi; Alfred L M Bothwell
Journal:  Mol Cells       Date:  2012-02-28       Impact factor: 5.034

Review 6.  Activation of PPARδ: from computer modelling to biological effects.

Authors:  Shirin Kahremany; Ariela Livne; Arie Gruzman; Hanoch Senderowitz; Shlomo Sasson
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

Review 7.  Peroxisome proliferator-activated receptor (PPAR): balance for survival in parasitic infections.

Authors:  Marion M Chan; Kyle W Evans; Andrea R Moore; Dunne Fong
Journal:  J Biomed Biotechnol       Date:  2010-02-10

8.  Cross-Talk between PPARgamma and Insulin Signaling and Modulation of Insulin Sensitivity.

Authors:  Anna Leonardini; Luigi Laviola; Sebastio Perrini; Annalisa Natalicchio; Francesco Giorgino
Journal:  PPAR Res       Date:  2010-02-23       Impact factor: 4.964

9.  Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs.

Authors:  Thomas J Urban; Yufeng Shen; Andrew Stolz; Naga Chalasani; Robert J Fontana; James Rochon; Dongliang Ge; Kevin V Shianna; Ann K Daly; M Isabel Lucena; Matthew R Nelson; Mariam Molokhia; Guruprasad P Aithal; Aris Floratos; Itsik Pe'er; Jose Serrano; Herbert Bonkovsky; Timothy J Davern; William M Lee; Victor J Navarro; Jayant A Talwalkar; David B Goldstein; Paul B Watkins
Journal:  Pharmacogenet Genomics       Date:  2012-11       Impact factor: 2.089

10.  Current understanding of the role of PPARγ in gastrointestinal cancers.

Authors:  Bing Zou; Liang Qiao; Benjamin C Y Wong
Journal:  PPAR Res       Date:  2009-10-26       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.